非アルコール性脂肪性肝炎：パイプライン分析

非アルコール性脂肪性肝炎(NASH)とは、肝臓に蓄積された脂肪肝により引き起こされる炎症です。肝臓の瘢痕化を発生・悪化させ、それがさらに硬変の原因ともなっています。主な症状には、倦怠感や原因不明の体重減少、全身の衰弱、腹部右側の腹痛などがあります。疾病素質として、肥満や2型糖尿病、高コレステロール、高中性脂肪（トリグリセリド）、メタボリック症候群などがあります。

当レポートでは、世界各国での非アルコール性脂肪性肝炎治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

• 分析範囲

非アルコール性脂肪性肝炎の概要

治療薬の開発

• 非アルコール性脂肪性肝炎向けパイプライン製品：概要
• 非アルコール性脂肪性肝炎向けパイプライン製品：比較分析

各企業で開発中の非アルコール性脂肪性肝炎治療薬

大学／研究機関で研究中の非アルコール性脂肪性肝炎治療薬

パイプライン製品の概略

• 後期段階の製品
• 治験段階の製品
• 初期段階の製品

非アルコール性脂肪性肝炎治療薬：開発中の製品の一覧（企業別）

非アルコール性脂肪性肝炎治療薬：研究中の製品の一覧（大学／研究機関別）

非アルコール性脂肪性肝炎治療薬の開発に従事している企業

• AlbireoPharma
• Alnylam Pharmaceuticals, Inc.
• Aquinox Pharmaceuticals Inc.
• Arbutus Biopharma Corporation
• Arisaph Pharmaceuticals, Inc.
• AstraZeneca Plc
• BiOrion Technologies B.V.
• Bird Rock Bio, Inc.
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Can-Fite BioPharma Ltd.
• Cardax Pharmaceuticals, Inc.
• Cerenis Therapeutics Holding SA
• Conatus Pharmaceuticals Inc.
• Connexios Life Sciences Pvt. Ltd.
• 第一三共
• Dr. Falk Pharma GmbH
• DURECT Corporation
• Dynavax Technologies Corporation
• Enanta Pharmaceuticals, Inc.
• Exicure, Inc.
• F. Hoffmann-La Roche Ltd.
• Galectin Therapeutics, Inc.
• Galmed Pharmaceuticals Ltd.
• Genfit SA
• GenKyoTex S.A.
• Gilead Sciences, Inc.
• Immuron Limited
• Intercept Pharmaceuticals, Inc.
• Inventiva SAS
• Ionis Pharmaceuticals, Inc.
• Jenrin Discovery, Inc.
• キッセイ薬品工業
• キョーリン製薬
• Medivation, Inc.
• Merck & Co., Inc.
• Metabolic Solutions Development Company, LLC
• Naia Limited
• NGM Biopharmaceuticals, Inc.
• Nimbus Therapeutics, LLC
• 日本ケミファ
• Nitto Denko Corporation
• Novartis AG
• NovaTarg Therapeutics, Inc
• Novo Nordisk A/S
• Pharmaxis Limited
• Promethera Biosciences S.A.
• ProMetic Life Sciences Inc.
• Protalix BioTherapeutics, Inc.
• Regulus Therapeutics Inc.
• Shire Plc
• Stelic Institute & Co., Inc.
• TaiwanJ Pharmaceuticals Co., Ltd.
• Therapix Biosciences Ltd
• Tobira Therapeutics, Inc.
• Vascular Biogenics Ltd.
• Verlyx Pharma Inc.
• Verva Pharmaceuticals Limited
• Viking Therapeutics, Inc.
• Virobay Inc.
• Zafgen Inc.
• Zydus Cadila Healthcare Limited

非アルコール性脂肪性肝炎：治療薬の評価

• 単剤治療薬の場合
• 併用製品
• 標的別
• 作用機序別
• 投与方法別
• 分子の種類別

薬剤のプロファイル

• (ロイシン + 塩酸メトホルミン + クエン酸シルデナフィル) 製品概要
  • 機能メカニズム
  • 研究開発(R&D)の進展状況

• (ロイシン + PDE5 インヒビター)
• A-4250
• AM-0010
• AQX-1125
• Aramchol
• ARI-3037MO
• bertilimumab
• BMS-986036
• BMS-986171
• BOT-191
• CDX-085
• cenicriviroc mesylate
• CER-209
• CF-102
• CNX-014
• CNX-023
• CNX-024
• CNX-025
• DRX-065
• DUR-928
• DV-1179
• EDP-305
• elafibranor
• emricasan
• etanercept のバイオシミラー
• GKT-831
• GRMD-02
• GS-9674
• HepaStem
• IMM-124E
• IONIS-DGAT2Rx
• IVA-337
• JD-5037
• JKB-119
• JKB-121
• linagliptin
• liraglutide (組換型)
• LJN-452
• MAT-8800
• MDV-4463
• methazolamide
• 循環器系/中枢神経系/消化器/免疫/代謝性疾患・感染症向け CD3阻害モノクローナル抗体
• MSDC-0602
• NC-101
• NC-2400
• ND-630
• ND-654
• ND-L02s0201
• NDI-010976
• NGM-282
• norursodeoxycholic acid
• NP-201
• obeticholic acid
• 非アルコール性脂肪性肝炎向けオリゴヌクレオチド
• PBI-4050
• pentamidine isethionate
• Px-103
• PXS-4728A
• PXS-5033A
• PZ-235
• remogliflozin etabonate
• RG-125
• RG-6125
• 循環器疾患・代謝障害・非アルコール性脂肪性肝炎向け RNAiオリゴヌクレオチド
• RYI-018
• saroglitazar
• selonsertib
• simtuzumab
• 非アルコール性脂肪性肝炎向け小分子
• 非アルコール性脂肪性肝・非アルコール性脂肪肝疾患向け小分子
• 非アルコール性脂肪性肝炎向け SCD-1阻害剤
• 脂肪肝疾患向け AMPK活性剤
• 非アルコール性脂肪性肝炎向け MLK3阻害剤
• solithromycin
• SR-9238
• STNM-09
• TGFTX-3
• tipelukast
• TKM-HTG
• TRX-318
• VB-201
• VBY-376
• VK-0214
• VK-2809
• volixibat potassium
• VVP-100-X
• ZGN-839
• ■非アルコール性脂肪性肝炎治療薬：パイプライン製品の最新動向

非アルコール性脂肪性肝炎治療薬：開発が休止状態の製品

非アルコール性脂肪性肝炎治療薬：開発が中止された製品

非アルコール性脂肪性肝炎関連製品の開発のマイルストーン

• 注目すべき最新動向・プレスリリース

付録

図表一覧

List of Tables

• Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), H1 2019
• Number of Products under Development by Companies, H1 2019
• Number of Products under Development by Universities/Institutes, H1 2019
• Products under Development by Companies, H1 2019
• Products under Development by Universities/Institutes, H1 2019
• Number of Products by Stage and Target, H1 2019
• Number of Products by Stage and Mechanism of Action, H1 2019
• Number of Products by Stage and Route of Administration, H1 2019
• Number of Products by Stage and Molecule Type, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by 3-V Biosciences Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by 89bio Ltd, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Abide Therapeutics Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by AdAlta Ltd, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Akcea Therapeutics Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Akero Therapeutics Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Albireo Pharma Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Aldeyra Therapeutics Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Allergan Plc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Allinky Biopharma SL, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Alteogen Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Angion Biomedica Corp, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Araim Pharmaceuticals Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Arcturus Therapeutics Ltd, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Ardelyx Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Ascletis Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Assembly Biosciences Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by AstraZeneca Plc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Betagenon AB, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by BioElectron Technology Corp, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Bird Rock Bio Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by BLR Bio LLC, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Boehringer Ingelheim GmbH, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Bristol-Myers Squibb Co, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Cadila Healthcare Ltd, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Can-Fite BioPharma Ltd, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Carmot Therapeutics Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Celgene Corp, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Cerenis Therapeutics Holding SA, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by ChemoCentryx Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by CJ HealthCare Corp, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by CohBar Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Coherus BioSciences Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by ConSynance Therapeutics Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by ContraVir Pharmaceuticals Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Corcept Therapeutics Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by CymaBay Therapeutics Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Daiichi Sankyo Co Ltd, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Debiopharm International SA, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Dicerna Pharmaceuticals Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Dimerix Bioscience Pty Ltd, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by DURECT Corp, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Eli Lilly and Co, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Enanta Pharmaceuticals Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Enyo Pharma SA, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Esperion Therapeutics Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Exicure Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Forma Therapeutics Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Galectin Therapeutics Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Galecto Biotech AB, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Galmed Pharmaceuticals Ltd, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Gemphire Therapeutics Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Genfit SA, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by GenKyoTex SA, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Gilead Sciences Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by GRI Bio Inc, H1 2019
• Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H1 2019

List of Figures

• Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), H1 2019
• Number of Products under Development by Companies, H1 2019
• Number of Products under Development by Universities/Institutes, H1 2019
• Number of Products by Top 10 Targets, H1 2019
• Number of Products by Stage and Top 10 Targets, H1 2019
• Number of Products by Top 10 Mechanism of Actions, H1 2019
• Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
• Number of Products by Top 10 Routes of Administration, H1 2019
• Number of Products by Stage and Top 10 Routes of Administration, H1 2019
• Number of Products by Top 10 Molecule Types, H1 2019
• Number of Products by Stage and Top 10 Molecule Types, H1 2019

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H1 2019, provides an overview of the Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline landscape.

Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 40, 42, 1, 5, 143, 49 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.

Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

• The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).

• The pipeline guide reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

• The pipeline guide reviews key companies involved in Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics and enlists all their major and minor projects.

• The pipeline guide evaluates Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

• The pipeline guide reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal)

Reasons to buy:

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

• Find and recognize significant and varied types of therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).

• Classify potential new clients or partners in the target demographic.

• Develop tactical initiatives by understanding the focus areas of leading companies.

• Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

• Formulate corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

• Introduction
• Non-Alcoholic Steatohepatitis (NASH) - Overview
• Non-Alcoholic Steatohepatitis (NASH) - Therapeutics Development
• Non-Alcoholic Steatohepatitis (NASH) - Therapeutics Assessment
• Non-Alcoholic Steatohepatitis (NASH) - Companies Involved in Therapeutics Development
• Non-Alcoholic Steatohepatitis (NASH) - Drug Profiles
• Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects
• Non-Alcoholic Steatohepatitis (NASH) - Discontinued Products
• Non-Alcoholic Steatohepatitis (NASH) - Product Development Milestones
• Appendix